3D Medicines surged more than 13% during the trading session, and its Chinese name was changed to Sillvaco Biopharma Co., effective next week.

3D MEDICINES(01244) is up more than 13% at midday, and is up 3.61% at the time of writing, trading at HK$4.02, with a turnover of HK$9.5173 million.

On the news, 3D MEDICINES announced that the adoption of "Sinosure Pharmaceutical Co., Ltd." as the company's Chinese dual English name has taken effect. The Chinese abbreviated name of the shares traded on the Stock Exchange of Hong Kong, "Sinosure Pharmaceutical Shares" will take effect from 9:00 a.m. on August 5, 2024. The English abbreviated name of the shares, "3D MEDICINES" and the stock code "1244" as well as other trading arrangements related to the shares will remain unchanged.

It is worth noting that the US biotech company TRACON announced recently that it would stop further development due to Enovli's monoclonal antibody failing to reach the primary endpoint in the clinical trial. According to the announcement, Enovli's rights in China are shared by CanSino, Sinosure Pharmaceutical, Simcere Pharmaceutical, and three companies. Sinosure Pharmaceutical and CanSino respectively enjoy 49% and 51% of the pre-tax profits. The financial report shows that the revenue from Envida (Enovli, subcutaneous injection PD-L1) was RMB636.5 million in 2023, up 11.9% YoY. As the only product that has achieved commercialization, this part of the revenue is exactly the company's annual total revenue.